Hospital

Investigators from University of Texas Health Science Center at Houston analyze data from individuals aged 5 to 18 years enrolled in the Texas CARES survey.

Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.

Analysis looks at those with arthritis, chronic pain, headaches, lower back pain, and neuropathic pain between 2012 and 2019.

Scientists found that inhibiting certain immune system receptors could treat colon cancer and other diseases of the gastrointestinal tract.

The Oncomine Dx Target Test is a next-generation sequencing–based companion diagnostic developed to analyze 23 genes associated with non–small cell lung cancer in patients who harbor an activating HER2 mutation.

A new study found that reduced tobacco use lowered deaths, person-years of lost life, and lost earnings across many states nationwide.

Zoledronic acid (Zometa) is indicated for the treatment of hypercalcemia that may occur with cancer.

Researchers discovered that a common anti-inflammatory drug could lower the number of patients on ventilators from COVID-19, increasing the likelihood of survival by more than 50%.

Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.

With costs for blood and blood products continuing to rise, appropriate blood use by hospitals is more important than ever.

A new study warns that fluoroquinolone could increase the risk of altered mental status and hospitalizations for advanced chronic kidney disease patients, though it is rare.

Insurer and pharmacy benefit manager policies used to cut the cost of drugs could be so time consuming that they could put newly diagnosed atrial fibrillation patients at risk of stroke.

A potential public health benefit of 13-valent pneumococcal conjugate vaccine is the reduction of acute chest syndrome among children with sickle-cell disease.

Experts predict a bad flu season in the US in 2022, noting children and pregnant women in their third trimester are recommended to be the first in line for flu vaccination.

Humate-P is indicated for the treatment of adult patients with classical hemophilia (hemophilia A) and von Willebrand disease (VWD).

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Treatment with biologic disease-modifying antirheumatic drugs associated with a higher overall risk, incidence, and recurrence of herpes zoster for patients with rheumatoid arthritis.

Study finds link between higher insulin doses and the risk of developing cancer in patients with type 1 diabetes.

New research links some beta-blockers and antiplatelet medications with a higher risk of experiencing a heart attack in hot weather.

The FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu) to treat HER2 mutant non-small cell lung cancer was based on results from the DESTINY-Lung02 phase 2 trial.

Meropenem and vaborbactam is indicated for the treatment of complicated urinary tract infections for patients aged 18 years and older.

Baloxavir marboxil is the first and only single-dose oral medicine to treat influenza in children, a population who play a significant role as transmitters of influenza in the country.

Health care providers’ recommendations will make a difference, results of a new poll from the University of Michigan show.

Topline results from the KarMMa-3 trial show that idecabtagene vicleucel significantly improves progression-free survival vs standard regimens.

New study shows that race does not influence outcomes from immunotherapy for aggressive triple-negative breast cancer.

The Prescription Information Modernization Act seeks to modernize health care with up-to-date digital prescribing information to pharmacists.

A daily serving of meat can increase the risk of cardiovascular disease by 22% and our own gut microbes may contribute to this risk.

A recent study suggests that homologous and heterologous vaccines protect against the Omicron variant of COVID-19, but the heterologous appears more durable.

The interim analysis of the TROPION-Lung02 trial demonstrate an overall response rate of 37% in individuals who were treated with datopotamab deruxtecan and pembrolizumab.

There are several key areas of risk that infusion practices are likely to face at some point, and proactively preparing for these events can help ensure a positive outcome.